SLNO has been in the news 316% more than usual
Mar 20, 2026, 8:32 AM
17.41%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
SLNO has been in the news recently: Soleno Therapeutics, Inc. (SLNO) is facing a class action lawsuit for allegedly misleading investors about the safety of its drug candidate DCCR, which led to a 26% drop in stock prices. The lawsuit, which involves multiple law firms, concerns statements made between March 26 and November 4, 2025, that are claimed to have affected shareholders.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.